 LA JOLLA, Calif., Aug. 04, 2020 GLOBE NEWSWIRE -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market NASDAQ:MNOV and the JASDAQ Market of the Tokyo Stock Exchange Code Number: 4875, today announced that MediciNova will participate in the Morgan Stanley Virtual 18th Annual Global Healthcare Conference which will be held from September 14 - 18, 2020. Yuichi Iwaki, MD, PhD, President and Chief Executive Officer, and Geoffrey OBrien, JDMBA, Vice President and Executive Officer, will be available for one-on-one meetings at this conference and investors may request a one-on-one meeting through Morgan Stanley. About MediciNovaMediciNova, Inc. is a publicly traded biopharmaceutical company focused on developing novel therapeutics for the treatment of diseases with high unmet medical needs with a primary commercial focus on the U.S. market. MediciNovas current strategy is to focus on BC-PIV vaccine for COVID-19, MN-166 ibudilast for neurological disorders such as progressive multiple sclerosis MS, amyotrophic lateral sclerosis ALS, degenerative cervical myelopathy DCM, glioblastoma GBM, and substance dependence e.g., alcohol use disorder, methamphetamine dependence, opioid dependence, as well as prevention of acute respiratory distress syndrome ARDS caused by COVID-19, and MN-001 tipelukast for fibrotic diseases such as nonalcoholic steatohepatitis NASH and idiopathic pulmonary fibrosis IPF. MediciNovas pipeline also includes MN-221 bedoradrine and MN-029 denibulin. For more information on MediciNova, Inc., please visit in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the future development and efficacy of BC-PIV vaccine, MN-166, MN-001, MN-221, and MN-029. These forward-looking statements may be preceded by, followed by or otherwise include the words believes, expects, anticipates, intends, estimates, projects, can, could, may, will, would, considering, planning or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to, risks of obtaining future partner or grant funding for development of MN-166, MN-001, MN-221, and MN-029 and risks of raising sufficient capital when needed to fund MediciNovas operations and contribution to clinical development, risks and uncertainties inherent in clinical trials, including the potential cost, expected timing and risks associated with clinical trials designed to meet FDA guidance and the viability of further development considering these factors, product development and commercialization risks, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks associated with the reliance on third parties to sponsor and fund clinical trials, risks regarding intellectual property rights in product candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials, and the timing of expected filings with the regulatory authorities, MediciNovas collaborations with third parties, the availability of funds to complete product development plans and MediciNovas ability to obtain third party funding for programs and raise sufficient capital when needed, and the other risks and uncertainties described in MediciNovas filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2019 and its subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.INVESTOR CONTACT: Geoff OBrien Vice President MediciNova, Inc. 